Business
Matricelf to Attend The Digital Spine & Pain Neuroscience Summit 2026 in Phoenix, Arizona
Matricelf Ltd. (TASE: MTLF), a regenerative medicine company advancing personalized curative treatments for spinal cord injury, announced that it will attend the Digital Spine & Pain Neuroscience Summit 2026 (DSPN Spine Summit) being held in Phoenix, AZ between the February 26th to March 1st. The Summit is one of the premier global gatherings for clinicians, researchers, industry leaders, and innovators focused on spine care, neuroscience, and advanced therapeutic technologies.
About this update from Matricelf Ltd.
[{"type":"text","content":"PHOENIX and NESS ZIONA, Israel, Feb. 26, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company advancing personalized curative treatments for spinal cord injury, announced that it will attend the Digital Spine & Pain Neuroscience Summit 2026 (DSPN Spine Summit) being held in Phoenix, AZ between the February 26th to March 1st. The Summit is one of the premier global gatherings for clinicians, researchers, industry leaders, and innovators focused on spine care, neuroscience, and advanced therapeutic technologies.","length":548,"tagName":"p"},{"type":"text","content":"The DSPN Spine Summit, featuring a comprehensive agenda of cutting edge scientific sessions, expert panels, and emerging technology showcases provides a unique forum for advancing collaboration across the spine and regenerative medicine community.","length":247,"tagName":"p"},{"type":"text","content":"Matricelf at the Summit","length":23,"tagName":"p"},{"type":"text","content":"Matricelf's senior team will participate in the Summit to:","length":62,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Engage with key opinion leaders, clinicians and researchers in spinal cord injury and regenerative medicine.","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Present the Company's personalized neural tissue regeneration platform and clinical development strategy.","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Explore strategic partnerships that could support clinical translation, commercialization and broader adoption of Matricelf's therapies.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Highlight recent milestones, including ethical approvals and pre-clinical progress toward first in human studies.","length":113,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":470,"olType":false},{"type":"text","content":"Attending this conference reinforces Matricelf's commitment to advancing breakthrough regenerative therapies and enhancing outcomes for patients with paralysis due to spinal cord injury.","length":190,"tagName":"p"},{"type":"text","content":"Statement from Management","length":25,"tagName":"p"},{"type":"text","content":"Gil Hakim, CEO of Matricelf, said: "We are pleased to participate in the DSPN Spine Summit, where leading clinicia...